Evidence map›Paper›PMID 40168118›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

PHLPP2 is a pseudophosphatase that lost activity in the metazoan ancestor.

Tarik Husremović, Vanessa Meier, Lucas Piëch, Katharina M Siess, Sumire Antonioli, Irina Grishkovskaya, Nikoleta Kircheva, Silvia E Angelova, Karoline Wenzl, Andreas Brandstätter and 15 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. PHLPP is neither a Phosphatase nor a Tumor Suppressor.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. PHLPP2 is a pseudophosphatase that lost activity in the metazoan ancestor.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tarik Husremović *Max Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Vanessa Meier *Max Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Lucas PiëchMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Katharina M SiessMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Sumire AntonioliMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Irina GrishkovskayaResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna 1030, Austria.ORCID 0000-0003-0164-9373
Nikoleta KirchevaInstitute of Optical Materials and Technologies "Acad. J. Malinowski", Bulgarian Academy of Sciences, Sofia 1113, Bulgaria.
Silvia E AngelovaInstitute of Optical Materials and Technologies "Acad. J. Malinowski", Bulgarian Academy of Sciences, Sofia 1113, Bulgaria.ORCID 0000-0003-4717-8028
Karoline WenzlMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Andreas BrandstätterDepartment of Chemistry, Institute of Analytical Chemistry, University of Natural Resources and Life Sciences, Vienna 1190, Austria.ORCID 0009-0001-5230-5477
Jiri VeisMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Fran Miočić-StošićMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Dorothea AnratherMax Perutz Labs, Mass Spectrometry Facility, Vienna Biocenter Campus, Vienna 1030, Austria.ORCID 0000-0003-1677-2403
Markus HartlMax Perutz Labs, Mass Spectrometry Facility, Vienna Biocenter Campus, Vienna 1030, Austria.ORCID 0000-0002-4970-7336
Linda TruebesteinMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Luis M Cerron-AlvanMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Martin LeebMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.
Bojan ŽagrovićMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.ORCID 0000-0003-3814-3675
Stephan HannDepartment of Chemistry, Institute of Analytical Chemistry, University of Natural Resources and Life Sciences, Vienna 1190, Austria.ORCID 0000-0001-5045-7293
Christoph BockResearch Center for Molecular Medicine, Austrian Academy of Sciences, Vienna 1090, Austria.ORCID 0000-0001-6091-3088
Egon OgrisMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.ORCID 0000-0001-5950-9264
Todor DudevFaculty of Chemistry and Pharmacy, Sofia University "St. Kliment Ohridski", Sofia 1164, Bulgaria.ORCID 0000-0002-8186-2141
Nicholas A T IrwinGregor Mendel Institute, Austrian Academy of Sciences, Vienna BioCenter, Vienna 1030, Austria.
David HaselbachResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna 1030, Austria.ORCID 0000-0002-5276-5633
Thomas A LeonardMax Perutz Labs, University of Vienna and Medical University of Vienna, Vienna 1030, Austria.ORCID 0000-0001-6853-666X

Funding

Austrian Academy of Sciences (OEAW) DOC FellowshipAustrian Science Fund (FWF) B112Austrian Science Fund (FWF) P33066Austrian Science Fund (FWF) P36212Austrian Science Fund (FWF) W1261OeAD-GmbH (OEAD) BG 05/2023
6 · The paper itself

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is a major regulator of cell and organismal growth. Consequently, hyperactivation of PI3K and its downstream effector kinase, Akt, is observed in many human cancers. Pleckstrin homology domain leucine-rich repeat-containing protein phosphatases (PHLPP), two paralogous members of the metal-dependent protein phosphatase family, have been reported as negative regulators of Akt signaling and, therefore, tumor suppressors. However, the stoichiometry and identity of the bound metal ion(s), mechanism of action, and enzymatic specificity of these proteins are not known. Seeking to fill these gaps in our understanding of PHLPP biology, we unexpectedly found that PHLPP2 has no catalytic activity in vitro. Instead, we found that PHLPP2 is a pseudophosphatase with a single zinc ion bound in its catalytic center. Furthermore, we found that cancer genomics data do not support the proposed role of PHLPP1 or PHLPP2 as tumor suppressors. Phylogenetic analyses revealed an ancestral phosphatase that arose more than 1,000 Mya, but that lost activity at the base of the metazoan lineage. Surface conservation indicates that while PHLPP2 has lost catalytic activity, it may have retained substrate binding. Finally, using phylogenomics, we identify coevolving genes consistent with a scaffolding role for PHLPP2 on membranes. In summary, our results provide a molecular explanation for the inconclusive results that have hampered research on PHLPP and argue for a focus on the noncatalytic roles of PHLPP1 and PHLPP2.

Indexed as

Phosphoprotein PhosphatasesAnimalsEvolution, MolecularHumansNuclear ProteinsPhylogenySignal TransductionNuclear ProteinsPHLPP1 protein, humanPHLPP2 protein, humanPhosphoprotein PhosphatasesAktcancerPHLPPphosphatasesignaling

Identifiers

PMID40168118
PMCPMC12002173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.